Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 12/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 3/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6957271 | 0.87 | KMT2A (0.45) | KMT2AHTR4KDM4EELANEF2 | |
| SCHEMBL29805676 | 0.84 | HTR4 (0.55) | KMT2AHTR4KDM4ECYP3A4HTR2A | |
| SCHEMBL1832626 | 0.84 | HTR4 (0.55) | KMT2AHTR4KDM4ECYP3A4HTR2A | |
| Hydrochloric Acid SCHEMBL1405875 | 0.83 | HTR4 (0.54) | KMT2AHTR4HTR2A | |
| SCHEMBL15174608 | 0.81 | KMT2A (0.47) | KMT2AHTR4KDM4EELANEF2 | |
| SCHEMBL6956554 | 0.79 | KMT2A (0.46) | KMT2AHTR4KDM4EELANEF2 | |
| SCHEMBL6956867 | 0.79 | KMT2A (0.46) | KMT2AHTR4KDM4EELANEF2 | |
| SCHEMBL6956548 | 0.79 | KMT2A (0.46) | KMT2AHTR4KDM4EELANEF2 | |
| SCHEMBL27679755 | 0.78 | SMN1; SMN2 (0.50) | KMT2AKDM4EELANECYP1A2CYP2C9 | |
| SCHEMBL31429285 | 0.78 | KMT2A (0.48) | KMT2AHTR4KDM4EELANEF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) | 2023-01-10 | — | — | US | disclosed |
| US-20200247764-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY TECHNOLOGY (ZA) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247764-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | KMT2A 1178/4885HTR4 820/4885KDM4E 2047/4885 |
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | KMT2A 1178/4885HTR4 820/4885KDM4E 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.